Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q3 Results Preview: Merck & Co., Merck KGaA

Executive Summary

Investors will be eager to hear updates on Merck & Co.'s Keytruda market share versus other PD-1/L1 competitors in lung cancer, as well as other indications; Merck KGaA followers are watching for what sort of start its Pfizer Inc.-partnered checkpoint inhibitor Bavencio and the new multiple sclerosis drug Mavenclad have got off to.

You may also be interested in...



Merck Calls It Quits On Anacetrapib

Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.

No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie

Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.

Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer

The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel